Biogen's treatment approach holds promise for MS, studies find

07/6/2011 | Mass High Tech (Boston)

Biogen Idec's treatment approach for multiple sclerosis promoted axonal remyelination and prevented an autoimmune response by inhibiting the activity of death receptor-6, according to results of in vivo and in vitro studies to be published in the Nature Medicine journal. "These data provide strong evidence that this targeted approach warrants further research and ultimately may lead to an important new way of treating demyelinating diseases, including MS," said Sha Mi, a neurobiology scientist at Biogen.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX